PDX1 and neoplasm: To identify metabolic determinants of response to immunotherapy in immunologically cold tumours, we exploited a clinically relevant model of PDAC, which involves orthotopic injection of the KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) cell line into the pancreas head of immunocompetent mice.